Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
The University of Texas MD Anderson Cancer Center · University Hospital Brno · +19 more institutions
Abstract
PURPOSE The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely because of toxicity. Acalabrutinib was shown to be efficacious and less toxic than ibrutinib in a head-to-head trial in chronic lymphocytic leukemia and therefore might lead to better outcomes in MCL. METHODS Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine (90 mg/m 2 once daily; days 1 and 2) and rituximab…
Citation impact
- FWCI
- 50.72
- Percentile
- 100%
- References
- 33
Authors
288Topics & keywords
- Bendamustine
- Medicine
- Mantle cell lymphoma
- Rituximab
- Oncology
- Lymphoma
- Internal medicine
- Cancer research
- Good health and well-being